Localization of the complement membrane attack complex inhibitor (CD59) in human conjunctiva and lacrimal gland
- 1 January 1994
- journal article
- research article
- Published by Taylor & Francis in Current Eye Research
- Vol. 13 (12) , 851-855
- https://doi.org/10.3109/02713689409015085
Abstract
Recent studies have established that complement is present in the eye and participates in ocular defense. The mechanisms by which ocular tissues are protected from bystander injury arising from local activation of the cascade, however, have not been characterized. Decay accelerating factor (DAF or CD55) and the membrane inhibitor of reactive lysis (MIRL or CD59) are cell surface regulatory proteins that protect blood cells from uptake of autologous C3b and polymerization of autologous C9 on their surfaces. In previous studies, we found that DAF is expressed in high levels on corneal, conjunctival, and lacrimal gland acinar surfaces. In this study we assayed ocular and lacrimal gland tissues for CD59. Immunohistochemical analyses demonstrated large amounts of the protein the same locations. The presence of CD59 in these sites is consistent with the proposal that CD59 functions together with DAF in protecting ocular tissues from autologous complement-mediated injury. Curr. Eye Res. 13: 851–855, 1994.Keywords
This publication has 22 references indexed in Scilit:
- H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complementCellular Immunology, 1990
- CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.The Journal of Experimental Medicine, 1989
- Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.Journal of Clinical Investigation, 1989
- Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositolMolecular Immunology, 1989
- Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids.The Journal of Experimental Medicine, 1987
- Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipidBiochemistry, 1986
- Decay-accelerating factor is present on cultured human umbilical vein endothelial cells.The Journal of Experimental Medicine, 1986
- Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.The Journal of Experimental Medicine, 1985
- Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.The Journal of Experimental Medicine, 1984
- Lacrimal immunoglobulins and complement quantified by counter-immunoelectrophoresis.British Journal of Ophthalmology, 1975